CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC

Julie R. Brahmer

doi:10.2217/EBO.12.28

CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC

Julie R. Brahmer

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.

Original language	English (US)
Title of host publication	Targeted Therapies for Non-Small-Cell Lung Cancer
Publisher	Future Medicine Ltd.
Pages	47-54
Number of pages	8
ISBN (Electronic)	9781780840468
ISBN (Print)	9781780841236
DOIs	https://doi.org/10.2217/EBO.12.28
State	Published - Oct 1 2012

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.2217/EBO.12.28

Fingerprint Dive into the research topics of 'CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC'. Together they form a unique fingerprint.

Cite this

@inbook{654b5ff5a8234aefa158d31768102b7f,

title = "CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC",

abstract = "The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.",

author = "Brahmer, {Julie R.}",

year = "2012",

month = oct,

day = "1",

doi = "10.2217/EBO.12.28",

language = "English (US)",

isbn = "9781780841236",

pages = "47--54",

booktitle = "Targeted Therapies for Non-Small-Cell Lung Cancer",

publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - CTLA-4 inhibitor

T2 - Ipilimumab for the treatment of NSCLC

AU - Brahmer, Julie R.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.

AB - The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84957388345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957388345&partnerID=8YFLogxK

U2 - 10.2217/EBO.12.28

DO - 10.2217/EBO.12.28

M3 - Chapter

AN - SCOPUS:84957388345

SN - 9781780841236

SP - 47

EP - 54

BT - Targeted Therapies for Non-Small-Cell Lung Cancer

PB - Future Medicine Ltd.

ER -

CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this